Get the latest news on ANGLE stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on ANPCF performance

Latest ANGLE Stock News | OTC:ANPCF | Benzinga

ANGLE PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.

ANGLE PLC

News

Press Releases

Angle PLC Announces Publication Demonstrates CTC Profiling Potential

Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients

ANGLE presents two posters at EACR

Angle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR

Angle PLC Announces Research on HER2 Assay Kit Showcased at AACR

Angle PLC Announces HER2 Presentation at SABCS

Angle PLC Announces Parsortix Used in Research Paper from ETH Zurich

Legal

Angle PLC Announces Analysis of CTC-DNA and ctDNA using Illumina assay

Angle PLC Announces Issue of LTIP Options and Share Options

Angle PLC Announces Results of Eisai Phase 2 pilot study

ANPCF

ANPCY

ANGLE

<p>Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE&#39;s laboratories in Guildford, UK, and follows the Company&#39;s development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial &pound;150,000 to ANGLE.</p>

Angle Inks New Commercial Agreement With AstraZeneca to Enhance DNA Damage Response Detection

Comments

ANGLE Stock News

News

Latest ANGLE Stock News | OTC:ANPCF | Benzinga

Wednesday, April 24, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga